PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW))) working in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI, Inc. (collectively "PetVivo" or the "Company"), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, today announced that it has entered into a Termination and Settlement Agreement with VetStem, Inc., effective July 24, 2026.

Under the agreement, the parties have terminated their Exclusive License and Supply Agreement relating to the PrecisePRP® product line, resolved all matters arising under the parties' prior Exclusive License and Supply Agreement, and established an orderly transition of the remaining PrecisePRP® inventory and related commercial activities. The Settlement Agreement further provides that, except for the payments expressly required thereunder, all financial obligations arising under the prior License Agreement have been fully satisfied and extinguished, including outstanding invoices, accrued royalty obligations, milestone payment obligations and other claims between the parties. The agreement includes mutual releases with respect to substantially all claims arising under the prior agreement, subject only to certain continuing obligations customary for agreements of this nature.

As a result of the comprehensive settlement, PetVivo's sole remaining financial obligation under the Settlement Agreement is the payment of an aggregate of $75,000, consisting of two scheduled cash payments. The Settlement Agreement also includes an inventory reconciliation mechanism pursuant to which PetVivo may be required to make an additional payment if the transferred inventory is determined to be less than the agreed minimum quantities following the parties' inventory verification process. The agreement further provides for the return of the remaining PrecisePRP® product inventory to VetStem. In addition, the Settlement Agreement confirms that the previously issued warrant held by VetStem to purchase 250,000 shares of PetVivo common stock remains in full force and effect in accordance with its existing terms.